LivaNova PLC (NASDAQ:LIVN) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of LivaNova PLC (NASDAQ:LIVN) have received an average rating of “Moderate Buy” from the nine research firms that are presently covering the company, MarketBeat.com reports. Three investment analysts have rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $79.3750.

Several analysts have issued reports on LIVN shares. Mizuho increased their target price on LivaNova from $85.00 to $90.00 and gave the company an “outperform” rating in a research report on Thursday, May 7th. Stifel Nicolaus set a $80.00 price objective on LivaNova in a report on Wednesday, February 25th. Needham & Company LLC increased their price objective on LivaNova from $64.00 to $81.00 and gave the company a “buy” rating in a report on Wednesday, February 25th. Barclays increased their price objective on LivaNova from $73.00 to $76.00 and gave the company an “equal weight” rating in a report on Thursday, May 7th. Finally, Piper Sandler reiterated an “overweight” rating and set a $85.00 price objective on shares of LivaNova in a report on Thursday, February 19th.

LivaNova Stock Down 1.8%

Shares of NASDAQ LIVN opened at $72.36 on Friday. The company has a current ratio of 1.33, a quick ratio of 1.11 and a debt-to-equity ratio of 0.24. The stock has a market capitalization of $3.97 billion, a PE ratio of 37.11 and a beta of 0.88. The stock’s fifty day simple moving average is $67.58 and its two-hundred day simple moving average is $64.94. LivaNova has a 12-month low of $41.01 and a 12-month high of $75.82.

LivaNova (NASDAQ:LIVN) last announced its earnings results on Wednesday, May 6th. The company reported $0.98 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.85 by $0.13. The business had revenue of $362.26 million for the quarter, compared to analysts’ expectations of $346.05 million. LivaNova had a return on equity of 16.48% and a net margin of 7.48%.The business’s revenue for the quarter was up 14.3% on a year-over-year basis. During the same quarter last year, the firm earned $0.88 EPS. LivaNova has set its FY 2026 guidance at 4.200-4.300 EPS. As a group, analysts expect that LivaNova will post 3.72 EPS for the current fiscal year.

Insider Activity at LivaNova

In other news, Director Francesco Bianchi sold 1,800 shares of the stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $75.75, for a total transaction of $136,350.00. Following the completion of the sale, the director owned 7,228 shares in the company, valued at approximately $547,521. This represents a 19.94% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.35% of the company’s stock.

Institutional Trading of LivaNova

Hedge funds and other institutional investors have recently made changes to their positions in the business. Hantz Financial Services Inc. lifted its holdings in shares of LivaNova by 159.9% during the 4th quarter. Hantz Financial Services Inc. now owns 434 shares of the company’s stock valued at $27,000 after purchasing an additional 267 shares during the last quarter. State of Wyoming purchased a new stake in shares of LivaNova during the 2nd quarter valued at $31,000. Quarry LP purchased a new stake in shares of LivaNova during the 3rd quarter valued at $36,000. EverSource Wealth Advisors LLC lifted its holdings in shares of LivaNova by 998.4% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 703 shares of the company’s stock valued at $32,000 after purchasing an additional 639 shares during the last quarter. Finally, Covestor Ltd lifted its holdings in shares of LivaNova by 108.6% during the 4th quarter. Covestor Ltd now owns 753 shares of the company’s stock valued at $46,000 after purchasing an additional 392 shares during the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

LivaNova Company Profile

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.